| 000 | 03292nlm1a2200517 4500 | ||
|---|---|---|---|
| 001 | 662556 | ||
| 005 | 20231030041825.0 | ||
| 035 | _a(RuTPU)RU\TPU\network\33711 | ||
| 035 | _aRU\TPU\network\5925 | ||
| 090 | _a662556 | ||
| 100 | _a20200902a2020 k y0engy50 ba | ||
| 101 | 0 | _aeng | |
| 135 | _adrcn ---uucaa | ||
| 181 | 0 | _ai | |
| 182 | 0 | _ab | |
| 200 | 1 |
_aKinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer _fA. Alhuseinalkhudhur, M. Lubberink, H. Lindman [et al.] |
|
| 203 |
_aText _celectronic |
||
| 300 | _aTitle screen | ||
| 320 | _a[References: 29 tit.] | ||
| 330 | _aHigh expression of human epidermal growth factor receptor type 2 (HER2) represents an aggressive subtype of breast cancer. Anti-HER2 treatment requires a theragnostic approach wherein sufficiently high receptor expression in biopsy material is mandatory. Heterogeneity and discordance of HER2 expression between primary tumour and metastases, as well as within a lesion, present a complication for the treatment and require multiple biopsies. Molecular imaging using the HER2-targeting Affibody peptide ABY-025 radiolabelled with 68Ga-gallium for PET/CT is currently under investigation as a non-invasive tool for whole-body evaluation of metastatic HER2 expression. Initial studies demonstrated a high correlation between 68Ga-ABY-025 standardized uptake values (SUVs) and histopathology. However, detecting small liver lesions might be compromised by high background uptake. This study aimed to explore the applicability of kinetic modelling and parametric image analysis for absolute quantification of 68Ga-ABY-025 uptake and HER2-receptor expression and how that relates to static SUVs. | ||
| 333 | _aРежим доступа: по договору с организацией-держателем ресурса | ||
| 461 | _tEJNMMI Research | ||
| 463 |
_tVol. 10, iss. 1 _v[21, 10 p.] _d2020 |
||
| 610 | 1 | _aэлектронный ресурс | |
| 610 | 1 | _aтруды учёных ТПУ | |
| 610 | 1 | _aHER2 receptor | |
| 610 | 1 | _ametastatic breast cancer | |
| 610 | 1 | _aaffibody | |
| 610 | 1 | _adynamic PET | |
| 610 | 1 | _akinetic modelling | |
| 610 | 1 | _aрецепторы | |
| 610 | 1 | _aметаструктуры | |
| 610 | 1 | _aрак | |
| 610 | 1 | _aкинетическое моделирование | |
| 701 | 1 |
_aAlhuseinalkhudhur _bA. _gAli |
|
| 701 | 1 |
_aLubberink _bM. _gMark |
|
| 701 | 1 |
_aLindman _bH. _gHenrik |
|
| 701 | 1 |
_aTolmachev _bV. M. _cspecialist in the field of medical technology _cDirector of the Research Center "Oncoteranostika", Tomsk Polytechnic University, Ph.D _f1961- _gVladimir Maksimilianovich _2stltpush _3(RuTPU)RU\TPU\pers\46552 |
|
| 701 | 1 |
_aFrejd _bF. Y. _gFredrik |
|
| 701 | 1 |
_aFeldwisch _bJ. _gJoachim |
|
| 701 | 1 |
_aVelikyan _bI. _gIrina |
|
| 701 | 1 |
_aSorensen _bJ. _gJens |
|
| 712 | 0 | 2 |
_aНациональный исследовательский Томский политехнический университет _bИсследовательская школа химических и биомедицинских технологий _c(2017- ) _h8120 _2stltpush _3(RuTPU)RU\TPU\col\23537 |
| 801 | 2 |
_aRU _b63413507 _c20200902 _gRCR |
|
| 856 | 4 | _uhttps://doi.org/10.1186/s13550-020-0603-9 | |
| 942 | _cCF | ||